S&P 500   4,580.34 (+1.49%)
DOW   34,671.16 (+1.91%)
QQQ   390.17 (+0.79%)
AAPL   163.76 (-0.61%)
MSFT   329.91 (-0.05%)
FB   309.76 (-0.27%)
GOOGL   2,862.67 (+1.48%)
AMZN   3,443.11 (-0.02%)
TSLA   1,082.14 (-1.17%)
NVDA   322.08 (+2.46%)
BABA   121.37 (-0.91%)
NIO   36.05 (-5.90%)
CGC   10.17 (+2.31%)
AMD   150.60 (+1.00%)
GE   95.62 (+2.82%)
MU   82.75 (-2.82%)
T   23.26 (+4.63%)
F   19.92 (+1.74%)
DIS   146.93 (+3.36%)
PFE   53.63 (-1.92%)
AMC   30.07 (+5.25%)
ACB   6.00 (-0.17%)
BA   201.00 (+6.81%)
S&P 500   4,580.34 (+1.49%)
DOW   34,671.16 (+1.91%)
QQQ   390.17 (+0.79%)
AAPL   163.76 (-0.61%)
MSFT   329.91 (-0.05%)
FB   309.76 (-0.27%)
GOOGL   2,862.67 (+1.48%)
AMZN   3,443.11 (-0.02%)
TSLA   1,082.14 (-1.17%)
NVDA   322.08 (+2.46%)
BABA   121.37 (-0.91%)
NIO   36.05 (-5.90%)
CGC   10.17 (+2.31%)
AMD   150.60 (+1.00%)
GE   95.62 (+2.82%)
MU   82.75 (-2.82%)
T   23.26 (+4.63%)
F   19.92 (+1.74%)
DIS   146.93 (+3.36%)
PFE   53.63 (-1.92%)
AMC   30.07 (+5.25%)
ACB   6.00 (-0.17%)
BA   201.00 (+6.81%)
S&P 500   4,580.34 (+1.49%)
DOW   34,671.16 (+1.91%)
QQQ   390.17 (+0.79%)
AAPL   163.76 (-0.61%)
MSFT   329.91 (-0.05%)
FB   309.76 (-0.27%)
GOOGL   2,862.67 (+1.48%)
AMZN   3,443.11 (-0.02%)
TSLA   1,082.14 (-1.17%)
NVDA   322.08 (+2.46%)
BABA   121.37 (-0.91%)
NIO   36.05 (-5.90%)
CGC   10.17 (+2.31%)
AMD   150.60 (+1.00%)
GE   95.62 (+2.82%)
MU   82.75 (-2.82%)
T   23.26 (+4.63%)
F   19.92 (+1.74%)
DIS   146.93 (+3.36%)
PFE   53.63 (-1.92%)
AMC   30.07 (+5.25%)
ACB   6.00 (-0.17%)
BA   201.00 (+6.81%)
S&P 500   4,580.34 (+1.49%)
DOW   34,671.16 (+1.91%)
QQQ   390.17 (+0.79%)
AAPL   163.76 (-0.61%)
MSFT   329.91 (-0.05%)
FB   309.76 (-0.27%)
GOOGL   2,862.67 (+1.48%)
AMZN   3,443.11 (-0.02%)
TSLA   1,082.14 (-1.17%)
NVDA   322.08 (+2.46%)
BABA   121.37 (-0.91%)
NIO   36.05 (-5.90%)
CGC   10.17 (+2.31%)
AMD   150.60 (+1.00%)
GE   95.62 (+2.82%)
MU   82.75 (-2.82%)
T   23.26 (+4.63%)
F   19.92 (+1.74%)
DIS   146.93 (+3.36%)
PFE   53.63 (-1.92%)
AMC   30.07 (+5.25%)
ACB   6.00 (-0.17%)
BA   201.00 (+6.81%)
OTCMKTS:CYYNF

Cynata Therapeutics Stock Forecast, Price & News

$0.40
0.00 (0.00%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.40
$0.40
50-Day Range
$0.33
$0.40
52-Week Range
$0.31
$0.66
Volume
N/A
Average Volume
2,991 shs
Market Capitalization
$38.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.69
30 days | 90 days | 365 days | Advanced Chart
Receive CYYNF News and Ratings via Email

Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Cynata Therapeutics logo

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Sanitary paper products
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CYYNF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$38.26 million
Optionable
Not Optionable

Company Calendar

Today
12/02/2021
Fiscal Year End
6/30/2022

MarketRank

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Cynata Therapeutics (OTCMKTS:CYYNF) Frequently Asked Questions

How has Cynata Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Cynata Therapeutics' stock was trading at $0.75 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CYYNF stock has decreased by 46.7% and is now trading at $0.40.
View which stocks have been most impacted by COVID-19
.

Who are Cynata Therapeutics' key executives?

Cynata Therapeutics' management team includes the following people:
  • Dr. Ross Alexander MacDonald Ph.D., MD, CEO & Exec. Director (Age 63, Pay $339.58k)
  • Dr. Kilian Kelly, Chief Operating Officer
  • Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. (Age 58, Pay $104.68k)
  • Dr. Suzanne Lipe, VP of Alliance Management (Age 71, Pay $162.76k)

What is Cynata Therapeutics' stock symbol?

Cynata Therapeutics trades on the OTCMKTS under the ticker symbol "CYYNF."

How do I buy shares of Cynata Therapeutics?

Shares of CYYNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cynata Therapeutics' stock price today?

One share of CYYNF stock can currently be purchased for approximately $0.40.

How much money does Cynata Therapeutics make?

Cynata Therapeutics has a market capitalization of $38.26 million.

What is Cynata Therapeutics' official website?

The official website for Cynata Therapeutics is www.cynata.com.

How can I contact Cynata Therapeutics?

The company can be reached via phone at 61 3 9824 5254.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.